Purpose: Histone deacetylase (HDAC) inhibitors have been shown to reverse epigenetic repression of certain genes, including retinoic acid receptor beta2 (RARbeta2). In this study, we examined whether RARbeta2 expression is repressed in human renal cell carcinoma (RCC) and whether the HDAC inhibitor MS-275 may revert its epigenetic repression.
Experimental Design: Six human tumor RCC cell lines were analyzed for RARbeta2 gene expression and for methylation and acetylation status at the promoter level. Modulation of RARbeta2 expression and correlation with antitumor activity by combination of MS-275 with 13-cis-retinoic acid (CRA) was assessed in a RARbeta2-negative RCC cell line.
Results: RARbeta2 expression was either strongly present, weakly expressed, or absent in the RCC cell lines analyzed. Methylation-specific PCR indicated that the RARbeta2 promoter was partially methylated in three of the cell lines. CRA treatment did not inhibit clonogenic growth in the RARbeta2-negative cell line RCC1.18, whereas MS-275 induced a dose-dependent inhibitory effect. A greater inhibitory effect was observed with combination treatment (MS-275 + CRA). Treatment with MS-275 was associated with histone acetylation at the promoter level and synergistic gene reexpression of RARbeta2 in combination with CRA. RARbeta2 reexpression was associated with synergistic induction of the retinoid-responsive gene HOXA5. In vivo, single-agent CRA treatment showed no significant effect, whereas MS-275 and the combination induced a regression of RCC1.18 tumor xenografts. Discontinuation of treatment produced tumor recurrence in MS-275-treated mice, whereas animals treated with the combination remained tumor free.
Conclusion: The HDAC inhibitor MS-275 seems to revert retinoid resistance due to epigenetic silencing of RARbeta2 in a human RCC model and has greater antitumor activity in combination with CRA compared with single agents. Thus, the combination of HDAC inhibitors and retinoids may represent a novel therapeutic approach in patients with RCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-04-1092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The HDAC Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2 Amplified Tumors and in Combination Therapies.
Cancer Res Treat
December 2024
Leipzig University, Medical Faculty, Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig, Germany.
Purpose: HER2 inhibition represents a therapeutic approach with proven clinical efficacy in gastric cancer. However, resistance against HER2-directed therapeutics highlights the need for alternative approaches or drug combinations. Histone deacetylase inhibitors (HDACi) display a broad spectrum of antitumor properties, which may include effects on receptor tyrosine kinases.
View Article and Find Full Text PDFEntinostat treatment causes hypophosphatemia and hypocalcemia by increasing Fgf23 in mice.
Biochem Biophys Res Commun
December 2024
Institute of Orthopaedics, Suzhou Medical College, Soochow University, Suzhou 215006, China; Department of Orthopedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. Electronic address:
Article Synopsis
- Entinostat, an HDACs-selective inhibitor being tested for cancer treatment, is linked to low phosphate and calcium levels during trials.
- Research indicates that while Entinostat increases trabecular bone volume, it does not affect cortical bone strength or key bone-forming and resorbing cells.
- The study highlights that Entinostat may elevate Fgf23 levels, leading to low phosphate and calcium, raising questions about its overall impact on bone health.
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.
Nat Commun
November 2024
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA.
Article Synopsis
- * In a Phase II clinical trial, 27 patients received entinostat followed by nivolumab, resulting in an objective response rate of 11% and a median response duration of over 10 months, although the primary endpoint for overall effectiveness was not reached.
- * The combination treatment led to significant immune profile changes, including increased dendritic cell activity and enhanced inflammatory response, suggesting potential for improving treatment strategies in PDA despite
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma.
J Exp Clin Cancer Res
October 2024
Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Article Synopsis
- Checkpoint immunotherapy struggles against non-immunogenic tumors like neuroblastoma due to low MHC class I expression and neoantigen burden, but inhibiting ERAP1 can enhance anti-tumor immune responses.
- A novel strategy combining genetic knockout of ERAP1 with the HDAC inhibitor entinostat was developed, leading to increased immunogenicity and making neuroblastoma more responsive to PD-1 therapy.
- Experimental methods included CRISPR/Cas9 gene editing, flow cytometry, and mass spectrometry to demonstrate that ERAP1 inhibition improves immune cell activity and increases MHC class I and PD-L1 expression in neuroblastoma cells, ultimately slowing tumor growth.
NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target.
Int J Biol Sci
October 2024
Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Nucleolar and spindle-associated protein 1 (NUSAP1), a microtubule-associated protein, has been recently identified to exhibit aberrant expression patterns that correlate with malignant tumorigenesis and progression across various cancer types. However, the specific regulatory mechanisms and potential targeting therapies of NUSAP1 in lung adenocarcinoma (LUAD) remain largely elusive. In this study, by conducting bioinformatics analyses as well as and experiments, we identified that NUSAP1 was significantly upregulated in LUAD, with a notable correlation with poorer overall survival, higher scores for immunogenicity and immune infiltration, as well as increased sensitivity to conventional chemotherapeutic drugs such as paclitaxel, docetaxel and vinorelbine in LUAD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!